Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
67
BSX Quote, Financials, Valuation and Earnings
Last price:
$90.36
Seasonality move
:
9.56%
Day range:
$88.36 - $89.99
52-week range:
$55.60 - $91.93
Dividend yield:
0%
P/E ratio:
74.26x
P/S ratio:
8.37x
P/B ratio:
6.40x
Volume:
3.8M
Avg. volume:
5.3M
1-year change:
60.75%
Market cap:
$132.4B
Revenue:
$14.2B
EPS (TTM):
$1.21
Analysts' Opinion
-
Consensus RatingBoston Scientific has received a consensus rating of Buy. The company's average rating is a Buy based on 21 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $99.14, Boston Scientific has an estimated upside of 10.33% from its current price of $89.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $83.00 representing 7.63% downside risk from its current price of $89.86.
Fair Value
-
According to the consensus of 26 analysts, Boston Scientific has 10.33% upside to fair value with a price target of $99.14 per share.
BSX vs. S&P 500
-
Over the past 5 trading days, Boston Scientific has underperformed the S&P 500 by -2.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Boston Scientific does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Boston Scientific has grown year-over-year revenues for 15 quarters straight. In the most recent quarter Boston Scientific reported revenues of $4.2B.
Earnings Growth
-
Boston Scientific earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Boston Scientific reported earnings per share of $0.32.
Enterprise value:
141.1B
EV / Invested capital:
4.43x
Price / LTM sales:
8.37x
EV / EBIT:
56.61x
EV / Revenue:
8.87x
PEG ratio (5yr expected):
1.56x
EV / Free cash flow:
74.56x
Price / Operating cash flow:
70.41x
Enterprise value / EBITDA:
37.86x
Gross Profit (TTM):
$11B
Return On Assets:
4.94%
Net Income Margin (TTM):
11.25%
Return On Equity:
8.91%
Return On Invested Capital:
5.95%
Operating Margin:
17.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $12.6B | $13.8B | $15.9B | $3.5B | $4.2B | |
| Gross Profit | $8.7B | $9.5B | $11B | $2.4B | $2.9B | |
| Operating Income | $2B | $2.3B | $2.8B | $609M | $718M | |
| EBITDA | $2.5B | $3.3B | $3.7B | $976M | $1.1B | |
| Diluted EPS | $0.42 | $0.82 | $1.21 | $0.34 | $0.32 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.2B | $6.2B | $5.1B | $6.5B | $8.8B | |
| Total Assets | $30.8B | $31.9B | $31.9B | $34B | $38.1B | |
| Current Liabilities | $3.3B | $4B | $3.5B | $4.6B | $5.9B | |
| Total Liabilities | $15.3B | $15.4B | $14.3B | $14.9B | $17.1B | |
| Total Equity | $15.6B | $16.5B | $17.6B | $19.1B | $21B | |
| Total Debt | $9.3B | $9.1B | $8.6B | $8.9B | $10.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.2B | $2.4B | $2.9B | $698M | $1B | |
| Cash From Investing | -$2.3B | -$1.7B | -$3B | -$197M | -$1.4B | |
| Cash From Financing | -$557M | -$9M | $1.6B | $16M | $7M | |
| Free Cash Flow | $524M | $1.6B | $1.9B | $492M | $698M | |
BSX
Sector
Market Cap
$132.4B
$45.6M
Price % of 52-Week High
97.75%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
60.75%
-31.35%
Beta (5-Year)
0.802
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$89.62
200-day SMA
Buy
Level
$78.81
Bollinger Bands (100)
Buy
Level
79.79 - 89.35
Chaikin Money Flow
Buy
Level
996M
20-day SMA
Sell
Level
$89.98
Relative Strength Index (RSI14)
Buy
Level
53.11
ADX Line
Buy
Level
8.11
Williams %R
Neutral
Level
-39.8618
50-day SMA
Buy
Level
$88.30
MACD (12, 26)
Buy
Level
0.27
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
681.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.9609)
Buy
CA Score
(Annual)
Level (0.2072)
Buy
Beneish M-Score
(Annual)
Level (-2.487)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.8967)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Stock Forecast FAQ
In the current month, BSX has received 21 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BSX average analyst price target in the past 3 months is $99.14.
-
Where Will Boston Scientific Stock Be In 1 Year?
According to analysts, the consensus estimate is that Boston Scientific share price will rise to $99.14 per share over the next 12 months.
-
What Do Analysts Say About Boston Scientific?
Analysts are divided on their view about Boston Scientific share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Boston Scientific is a Sell and believe this share price will drop from its current level to $83.00.
-
What Is Boston Scientific's Price Target?
The price target for Boston Scientific over the next 1-year time period is forecast to be $99.14 according to 26 Wall Street analysts, 21 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BSX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Boston Scientific is a Buy. 21 of 26 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BSX?
You can purchase shares of Boston Scientific via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Boston Scientific shares.
-
What Is The Boston Scientific Share Price Today?
Boston Scientific was last trading at $90.36 per share. This represents the most recent stock quote for Boston Scientific. Yesterday, Boston Scientific closed at $89.86 per share.
-
How To Buy Boston Scientific Stock Online?
In order to purchase Boston Scientific stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
